FSB Premier Wealth Management Inc. Has $707,000 Stake in Cencora, Inc. (NYSE:COR)

FSB Premier Wealth Management Inc. increased its holdings in shares of Cencora, Inc. (NYSE:COR) by 11.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,543 shares of the company’s stock after purchasing an additional 262 shares during the quarter. FSB Premier Wealth Management Inc.’s holdings in Cencora were worth $707,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. Price T Rowe Associates Inc. MD boosted its holdings in Cencora by 0.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company’s stock worth $1,990,542,000 after purchasing an additional 78,066 shares during the last quarter. Bank of America Corp DE boosted its holdings in Cencora by 62.3% during the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company’s stock worth $1,166,944,000 after purchasing an additional 1,994,256 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Cencora by 3.1% during the fourth quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company’s stock worth $969,471,000 after purchasing an additional 130,213 shares during the last quarter. Invesco Ltd. boosted its holdings in Cencora by 20.4% during the fourth quarter. Invesco Ltd. now owns 3,243,531 shares of the company’s stock worth $728,757,000 after purchasing an additional 550,246 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Cencora by 11.6% during the fourth quarter. Northern Trust Corp now owns 2,421,237 shares of the company’s stock worth $544,004,000 after purchasing an additional 252,028 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In related news, CEO Robert P. Mauch sold 4,968 shares of the firm’s stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the transaction, the chief executive officer directly owned 42,351 shares of the company’s stock, valued at approximately $12,455,852.61. This trade represents a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the firm’s stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the transaction, the chairman directly owned 311,913 shares in the company, valued at approximately $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,125 shares of company stock worth $9,993,789 over the last three months. Insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on COR shares. Robert W. Baird increased their target price on shares of Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Bank of America upped their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a “neutral” rating in a research report on Friday, April 11th. Jefferies Financial Group upped their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Finally, UBS Group upped their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a “buy” rating in a research report on Tuesday, April 29th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $309.83.

Cencora Price Performance

Shares of COR opened at $289.61 on Wednesday. The firm has a market capitalization of $56.13 billion, a PE ratio of 33.60, a PEG ratio of 1.42 and a beta of 0.57. The company’s 50-day moving average is $293.12 and its 200-day moving average is $275.23. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $309.35. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $3.80 earnings per share. Equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Cencora’s payout ratio is presently 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.